Neuro20 Technologies Receives the US FDA Clearance of Neuro20 PRO System for Treatment of Neuromuscular Injury and Disease
- The US FDA has cleared the 510(k)-pre-market approval application for Neuro20 PRO System that closes the loop b/w diagnostics & interventions in a wireless operating system. The system is designed to treat musculoskeletal injury & neuromuscular disease, stimulating over 42 muscles to enhance performance & promote recovery
- The results showed ~20% increase in maximum voluntary contraction, ~30% vascular dilation, and an increase in BDNF b/w 18%-30% depending on gene expression
- A whole-body electro-muscle stimulation suit & advanced software platform are combined in the Neuro20 PRO system to recreate specific functional movement patterns, strength, endurance & recovery. The system incl. 4 main programs with 9 additional modes for specific patient outcomes
Ref: Prnewswire | Image: Neuro20 Technologies
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].